Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Healthcare Biotechnology
Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Satellos Bioscience Inc > >>> ICO don't fall into the brutal fall trap to come <<<
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(20)
•••
Comment by juansitoon Apr 06, 2020 8:08pm
180 Views
Post# 30885002

RE:RE:RE:RE:RE:>>> ICO don't fall into the brutal fall trap to come <<<

RE:RE:RE:RE:RE:>>> ICO don't fall into the brutal fall trap to come <<<Sovy: everyone knows that you are a bag holder...
nobody is completely essencial, so Rae is gone but Ico still a company...with assets...
Please if you want to lower your average dont wait until 1cents bcz is not gonna happen...
try, like most of us to refill at 2.5 - 3 cents...
if this spike to 5-7c you can get out...for good...
I ll wait until 10c. not here for a penny flipp any more...
GLTA
completely essentialcompletely essential
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities